R&D News | pharmaphorum

News

Roche places a $1bn bet on C4T degrader-antibody conjugates

Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

23andMe study explains variable results with obesity drugs

Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.

News

Graphic of pile of gold coins and green shoots on blue background

Syneron raises $150m for macrocyclics, and other financings

Our round-up of recent biotech venture capital financings includes nine-figure rounds for Syneron, Stipple Bio, and Sidewinder.

News

Jeito's founder and president, Dr Rafaèle Tordjman

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Jeito Capital has closed its second fund, raking in €1bn, which it claims is the largest ever raise for an independent European biopharma fund.

News

EU invests €30m to fight antimicrobial resistance

The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.

Roche places a $1bn bet on C4T degrader-antibody conjugates

Pulmonary fibrosis drug developer Avalyn files IPO

23andMe study explains variable results with obesity drugs

Syneron raises $150m for macrocyclics, and other financings

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

EU invests €30m to fight antimicrobial resistance

EU warns of brain tumour risk with some contraceptives

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks